Dusunen Adam: The Journal of Psychiatry and Neurological Sciences最新文献_第10页

Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report 治疗性单剂量米氮平诱导症状性心动过缓1例报告

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-09-27 DOI: 10.5350/dajpn2018310309

Pınar D Gündoğmuş, İbrahim Gündoğmuş, Emrah Burak Olcu, A. Karagoz, A. Algul

{"title":"Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report","authors":"Pınar D Gündoğmuş, İbrahim Gündoğmuş, Emrah Burak Olcu, A. Karagoz, A. Algul","doi":"10.5350/dajpn2018310309","DOIUrl":"https://doi.org/10.5350/dajpn2018310309","url":null,"abstract":"Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report Cardiotoxicity is an important adverse effect of some psychotropic drugs. However, cardiac side effects with mirtazapine, which is used for an effective treatment of depression and anxiety, are rare. In this article, a forty-eight-year-old woman referred to psychiatric clinics with depressive symptoms. According to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria, major depressive disorder was diagnosed and mirtazapine 30mg/day was started. 30 minutes after the first dose of mirtazapine was brought to the emergency room with syncope, nausea, vomiting. She was examined in emergency service. Routine blood tests and ECG was studied. During the examination, the patient was followed up with a heart rate of 33 beats per minute, blood pressure arterial 80/50mmHg and a temperature of 36.1°C. 0.5mg atropine IV and theophylline inhaler were administered and cardiology consultation was requested. After atropine and theophylline administration, the heart rate was 48 beats/min in the second ECG. To the best of our knowledge, it is the first bradycardia developed after mirtazapine use in the literature. Bradycardia has been resolved after the half-life of mirtazapine has passed (37 hours for women). The initial heart rate of our patient was within normal limits prior to mirtazapine administration. There was no reason to explain bradycardia, we think that symptomatic bradycardine is caused by mirtazapine. In conclusion, this case report suggests that mirtazapine may cause bradycardia in patients. Risk factors for bradycardia caused by mirtazapine are unknown. Although in many patients this bradycardine does not cause a clinical outcome, clinicians should be aware of this and should perform ECG monitoring in patients with underlying cardiac disease, especially when prescribing mirtazapine.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87690730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The effect of heroin use disorder on the sexual functions of women 海洛因使用障碍对女性性功能的影响

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-09-27 DOI: 10.5350/DAJPN2018310301

M. Dişsiz

{"title":"The effect of heroin use disorder on the sexual functions of women","authors":"M. Dişsiz","doi":"10.5350/DAJPN2018310301","DOIUrl":"https://doi.org/10.5350/DAJPN2018310301","url":null,"abstract":"The effect of heroin use disorder on the sexual functions of women Objective: This study was conducted to evaluate the sexual functions of women with heroin use disorder. Method: This comparative-descriptive and cross-sectional study was carried out at the Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM) of Bakirkoy Training and Research Hospital for Psychiatry Neurology and Neurosurgery. Included in the heroin use disorder group were 57 women aged 18 years or above who presented to AMATEM between June 1, 2014 and December 31, 2014 and received a diagnosis of substance use disorder according to DSM-5. Inclusion criteria were the absence of psychiatric diseases, substance withdrawal symptoms, or mental retardation, being sexually active, not being pregnant or puerperant, and having given consent to participate in the study. Healthy female relatives of 79 female patients who presented to the Gynecology Clinic of the same hospital during the same period were included in the healthy group. The data were collected through an interview form was developed by researchers, Female Sexual Function Index (FSFI), and Beck Depression Inventory (BDI). Results: No difference was determined between the participants in both groups in terms of average age, period of education, body mass index, or employment and economic situation (p>0.05). It was determined that, in contrast with the healthy group, 70.4% of the women with heroin use disorder had sexual problems and 71.9% of them were not satisfied with their sexual life. It was found that women with heroin use disorder scored significantly lower than healthy controls in FSFI sub-dimensions such as desire, arousal, lubrication, orgasm, satisfaction, and pain, as well as for the total scale, while scores were higher on the BDI scale (p<0.05). Conclusion: Among women with heroin use disorder, sexual functions are adversely affected and depressive symptoms appear to be increased.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73309252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The challenge of responding to a more globally joined-up, dynamic, and innovative drug market: Reflections from the EMCDDA´s 2018 analysis of the European drug situation 应对更全球化、更有活力和更创新的药品市场的挑战:EMCDDA 2018年欧洲药品形势分析的思考

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-09-27 DOI: 10.5350/DAJPN20183103001

P. Griffiths, Eoghan Quigley, L. Vandam, Jane Mounteney

{"title":"The challenge of responding to a more globally joined-up, dynamic, and innovative drug market: Reflections from the EMCDDA´s 2018 analysis of the European drug situation","authors":"P. Griffiths, Eoghan Quigley, L. Vandam, Jane Mounteney","doi":"10.5350/DAJPN20183103001","DOIUrl":"https://doi.org/10.5350/DAJPN20183103001","url":null,"abstract":"Dusunen Adam The Journal of Psychiatry and Neurological Sciences, Volume 31, Number 3, September 2018 Each year in the European Drug Report (EDR), the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) produces an overview of trends and developments in the drug situation. Founded in 1993, and based in Lisbon, Portugal, since 1995, the EMCDDA is the designated reference point for drugrelated information in the European Union (EU). It works with all EU member states as well as, by special agreement, with Norway and Turkey. Data are collected annually for a set of standardised indicators that cover both drug demand and drug supply measures. In addition, the EMCDDA, together with Europol, is responsible for the EU’s early warning system on new psychoactive substances (NPS). This three-step mechanism allows for the sharing of information on non-controlled psychoactive substances appearing in Europe that may pose a risk to health similar to drugs controlled under the United Nations Conventions. Should it be merited, information provided to the early warning system may trigger a risk assessment, which is conducted by the EMCDDA’s Scientific Committee. This exercise can potentially lead to a decision for fast track control measures being introduced across the EU. In this editorial, we consider how a more globally joined-up, dynamic and innovative drug market has impacted on drug availability and on drug use problems. In doing so, we build on the commentary and analysis of the Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2018;31:231-237 Guest Editorial / Misafir Editoryal DOI: 10.5350/DAJPN20183103001","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78983196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Severe pseudocholinesterase deficiency and ECT: a case report 严重假胆碱酯酶缺乏伴电痉挛1例

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-09-27 DOI: 10.5350/DAJPN2018310311

E. Yıldızhan, N. Tomruk, Hafize Miray Aytac, H. Yıldırım, Ozge Canbek

引用次数: 2

Information processing abnormalities in schizophrenia and bipolar disorder 精神分裂症和双相情感障碍的信息处理异常

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-06-29 DOI: 10.5350/dajpn2018310202

Ozlem Devrim Balaban, Murat Ilhan Atagun, H. Devrimci Ozguven

{"title":"Information processing abnormalities in schizophrenia and bipolar disorder","authors":"Ozlem Devrim Balaban, Murat Ilhan Atagun, H. Devrimci Ozguven","doi":"10.5350/dajpn2018310202","DOIUrl":"https://doi.org/10.5350/dajpn2018310202","url":null,"abstract":"Information processing abnormalities in schizophrenia and bipolar disorder Objective: Patients with bipolar disorder and schizophrenia exhibit abnormalities in attention, memory, working memory, verbal/visual learning and executive functions. However, many of the tests fail to detect slight changes in cognitive performance due to ceiling effect. It was aimed to determine sensitivity and specificity of the tests that measure information processing in schizophrenia and bipolar disorder in this study. Method: Thirty four patients with schizophrenia, 35 patients with bipolar disorder according to DSM-IV and 33 healthy control subjects matched for age, education level and gender were enrolled to the study. For clinical assessments Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Hamilton Depression Rating Scale, Young Mania Rating Scale, Clinical Global Impression Scale and Abnormal Involuntary Movements Scale were used. All participants performed a battery consisting of tests measuring information processing including Adult Memory and Information Processing Battery (AMIPB), Trail Making Test (TMT) Form A and B, Digit Symbol Coding Task (DST) and Auditory and Visual Reaction Time Tests (RTT). Results: The schizophrenia group had significantly lower performance than the healthy control group in all tests and lower performance than the bipolar disorder group in AMIPBA and B tests, TMT A and B tests. The bipolar disorder group had lower performance than the healthy control group only in DST test. The AMIPB A and B tests were the most sensitive and specific tests in the ROC analysis. Conclusion: Changes in cognitive function might be better monitored by the tests whose sensitivity and specificity are higher. Since psychiatric disorders are highly heterogeneous, measurement tools are important for precise measurements.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80221761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hyperemesis gravidarum is associated with childhood trauma, depression, trait anxiety, and somatization: a case-control study 妊娠剧吐与儿童创伤、抑郁、特质焦虑和躯体化有关:一项病例对照研究

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-06-29 DOI: 10.5350/DAJPN2018310205

Y. Kıvrak, I. Yagci, Hacer Pasaoglu Yagci, Yasin Taşdelen, M. Aşoglu

{"title":"Hyperemesis gravidarum is associated with childhood trauma, depression, trait anxiety, and somatization: a case-control study","authors":"Y. Kıvrak, I. Yagci, Hacer Pasaoglu Yagci, Yasin Taşdelen, M. Aşoglu","doi":"10.5350/DAJPN2018310205","DOIUrl":"https://doi.org/10.5350/DAJPN2018310205","url":null,"abstract":"Hyperemesis gravidarum is associated with childhood trauma, depression, trait anxiety, and somatization: a case-control study Objective: Hyperemesis gravidarum (HG) is a disease characterized by severe nausea and vomiting; it is the most common cause of hospitalization in the first months of pregnancy. The effects of childhood trauma, anxiety types, and exaggeration of somatic sensations on HG have not been defined. In this study, it was aimed to investigate the relationship between HG and factors including depression, anxiety, childhood abuse, and exaggeration of physical sensations. Method: Forty-five pregnant women diagnosed with HG and 45 healthy pregnant women were included in the study. Socio-demographic data form, Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Somatosensory Amplification Scale (SSAS), Childhood Trauma Questionnaire (CTQ), and PregnancyUnique Quantification of Emesis (PUQE) scales were administered to the participants in the study. Results: No significant differences were observed between the groups in relation to socio-demographic data except income levels. The income level of the patient group was lower than that of the control group. Compared to the control group, scores for PUQE (p<0.01), BDI (p<0.01), Trait Anxiety Scale (TAI) (p<0.05), SSAS (p<0.05), and CTQ (p<0.001) were found to be significantly higher in the patient group. According to correlation analysis, while a relation was detected between PUQE scale results and CTQ, BDI, SSAS, and TAI results, no relation was found with the State Anxiety Inventory (SAI). Conclusion: In this study, a history of childhood trauma, depression, exaggeration of somatic sensations, and trait anxiety were found to be more common in individuals with HG. In addition, these factors were also found to be associated with the severity of nausea and vomiting.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74006091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Psychiatric presentation of hypoxic ischemic encephalopathy occurring after a violent suicide attempt: a case of hanging 暴力自杀未遂后出现的缺氧缺血性脑病的精神病学表现:一例上吊

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-06-29 DOI: 10.5350/DAJPN2018310214

Mehmet Hamdi Örüm, O. Eğilmez

引用次数: 7

Cyberchondria Scale (CS): Development, validity and reliability study 网络疑病症量表(CS)的开发、效度与信度研究

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-06-29 DOI: 10.5350/DAJPN2018310203

A. Batıgün, N. Gor, Burcu Komurcu, Ipek Senkal Erturk

引用次数: 35

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-06-29 DOI: 10.5350/DAJPN2018310207

Carmen Maura Carrillo de Albornoz, M. Guerrero-Jiménez, L. Gutiérrez-Rojas

{"title":"Sleep-related eating disorder caused by zolpidem: case report and review of the literature","authors":"Carmen Maura Carrillo de Albornoz, M. Guerrero-Jiménez, L. Gutiérrez-Rojas","doi":"10.5350/DAJPN2018310207","DOIUrl":"https://doi.org/10.5350/DAJPN2018310207","url":null,"abstract":"Sleep-related eating disorder caused by zolpidem: case report and review of the literature Sleep-related eating disorder (SRED) is a status characterized by recurrent episodes of eating high caloric foods and sometimes even toxic products at the transition from night-time sleep to arousal. The case presented is secondary to treatment with zolpidem, a hypnotic whose prescription rate has increased worldwide over the past few years. The authors report a case of SRED caused by zolpidem with important repercussions on the sleep structure and quality of life of our patient. The night eating episodes ceased promptly with zolpidem discontinuation, the sleep structure improved and the dayand night-time consequences disappeared. As in very few reported cases of zolpidem-induced SREDs, our patient had been suffering from parasomnia for a long time before the diagnosis. Reaching an understanding of the mechanism producing this type of parasomnias can be a guide for choosing the candidate profile before starting a zolpidem treatment. Active exclusion of symptoms suggestive of SREDs in patients under zolpidem treatment can avoid a significant deterioration in the quality of life of our patients. To our knowledge, there are no data focusing on the risk of parasomnias as a function of the sedative-hypnotic agent chosen. Here we present a case that may help address this issue.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80435370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Emergence of stuttering in an attention deficit hyperactivity disorder patient treated with methylphenidate 哌甲酯治疗的注意缺陷多动障碍患者出现口吃

Dusunen Adam: The Journal of Psychiatry and Neurological Sciences Pub Date : 2018-06-29 DOI: 10.5350/dajpn2018310212

M. Çopur, Sidar Copur

引用次数: 1